Summary
Quest Diagnostics Inc. (DGX) filed an 8-K report on May 19, 2017, detailing the results of its 2017 Annual Meeting of Stockholders held on May 16, 2017. The meeting primarily focused on voting matters, including the election of directors, advisory approval of executive compensation, the frequency of future advisory votes on executive compensation, ratification of the independent auditor, and amendments to the Long-Term Incentive Plan for Non-Employee Directors. All proposals presented to the shareholders received a majority of the votes cast, indicating broad shareholder support for the company's management and governance.
Key Highlights
- 1All nine director nominees were elected for terms expiring at the 2018 Annual Meeting, with substantial 'For' votes significantly outweighing 'Against' and 'Abstain' votes.
- 2Shareholders provided advisory approval for the executive officer compensation disclosed in the 2017 Proxy Statement, with a strong majority voting in favor.
- 3The frequency of the advisory vote on executive compensation was overwhelmingly set at '1 Year', indicating a preference for annual say-on-pay votes.
- 4The appointment of the Company's independent registered public accounting firm for 2017 was ratified with a very high level of shareholder approval.
- 5Amendments to the Amended and Restated Long-Term Incentive Plan for Non-Employee Directors were approved by shareholders, suggesting support for the company's director compensation structure.
- 6A significant number of 'Broker Non-Votes' were recorded for most proposals, which represent shares held by brokers that did not receive voting instructions from the beneficial owners.
Frequently Asked Questions
Yes, all nine director nominees presented at the 2017 Annual Meeting of Stockholders were elected for terms expiring at the 2018 Annual Meeting. The voting results show a clear majority of votes in favor of each nominee.
Shareholders provided advisory approval for the executive officer compensation. The resolution to approve the compensation disclosed in the 2017 Proxy Statement passed with a significant majority of 'For' votes.
The advisory vote on the frequency of future executive compensation votes indicated a strong preference from shareholders for an annual vote. The '1 Year' option received the largest number of votes by a substantial margin.
Yes, the ratification of the appointment of Quest Diagnostics' independent registered public accounting firm for 2017 was approved by the shareholders with a very high percentage of 'For' votes, indicating confidence in the chosen auditor.